DBV Technologies Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Public

  • Employees
  • 179

Employees

  • Stock Symbol
  • DBV

Stock Symbol

  • Share Price
  • $1.95
  • (As of Thursday Closing)

DBV Technologies General Information

Description

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Bâtiment IRO
  • 107 Av. de la République
  • 92320 Chatillon
  • France
+33 01
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
PAR
Vertical(s)
Corporate Office
  • Bâtiment IRO
  • 107 Av. de la République
  • 92320 Chatillon
  • France
+33 01

DBV Technologies Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DBV Technologies Stock Performance

As of 19-Nov-2026, DBV Technologies’s stock price is $1.95. Its current market cap is $612M with 314M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.95 $1.92 $1.72 - $5.29 $612M 314M 1.16M -$0.60

DBV Technologies Financials Summary

As of 30-Sep-2026, DBV Technologies has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 573,035 734,467 30,887 43,249
Revenue 0 0 0 0
EBITDA (205,463) (143,863) (109,044) (67,272)
Net Income (207,347) (146,947) (113,918) (72,726)
Total Assets 215,400 233,718 65,658 182,986
Total Debt 7,500 7,994 7,797 6,553
Public Fundamental Data provided by Morningstar, Inc. disclaimer

DBV Technologies Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore DBV Technologies‘s full profile, request access.

Request a free trial

DBV Technologies Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunothera
Biotechnology
Chatillon, France
179 As of 2026

Lyon, France
 

Tucson, AZ
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DBV Technologies Competitors (44)

One of DBV Technologies’s 44 competitors is Adocia, a Formerly VC-backed company based in Lyon, France.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adocia Formerly VC-backed Lyon, France
NuvOx Therapeutics Venture Capital-Backed Tucson, AZ
Ayala Pharmaceuticals Corporation Wilmington, DE
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
ArriVent Biopharma Formerly VC-backed Newtown Square, PA
You’re viewing 5 of 44 competitors. Get the full list »

DBV Technologies Patents

DBV Technologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024402685-A1 Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease Pending 21-Dec-2023
EP-4735036-A1 Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease Active 21-Dec-2023
EP-4735036-B1 Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease Active 21-Dec-2023
EP-4786006-A2 Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease Pending 21-Dec-2023
EP-4786006-A3 Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease Pending 21-Dec-2023 A61K39/35
To view DBV Technologies’s complete patent history, request access »

DBV Technologies Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DBV Technologies Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore DBV Technologies‘s full profile, request access.

Request a free trial

DBV Technologies ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

31.41 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view DBV Technologies’s complete esg history, request access »

DBV Technologies Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Dbv Pharma Paris, France 2018

DBV Technologies FAQs

  • When was DBV Technologies founded?

    DBV Technologies was founded in 2002.

  • Where is DBV Technologies headquartered?

    DBV Technologies is headquartered in Chatillon, France.

  • What is the size of DBV Technologies?

    DBV Technologies has 179 total employees.

  • What industry is DBV Technologies in?

    DBV Technologies’s primary industry is Biotechnology.

  • Is DBV Technologies a private or public company?

    DBV Technologies is a Public company.

  • What is DBV Technologies’s stock symbol?

    The ticker symbol for DBV Technologies is DBV.

  • What is the current stock price of DBV Technologies?

    As of 19-Nov-2026 the stock price of DBV Technologies is $1.95.

  • What is the current market cap of DBV Technologies?

    The current market capitalization of DBV Technologies is $612M.

  • Who are DBV Technologies’s competitors?

    Adocia, NuvOx Therapeutics, Ayala Pharmaceuticals, Dicerna Pharmaceuticals, and ArriVent Biopharma are some of the 44 competitors of DBV Technologies.

  • What is DBV Technologies’s annual earnings per share (EPS)?

    DBV Technologies’s EPS for 12 months was -$0.60.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process